Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - OMNI BIO PHARMACEUTICAL, INC.ex99-1.htm
EX-99.2 - EXHIBIT 99.2 - OMNI BIO PHARMACEUTICAL, INC.ex99-2.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
January 31, 2013
 
 
Omni Bio Pharmaceutical, Inc.
(Exact name of registrant as specified in its charter)
 
Colorado
000-52530
 20-8097969
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)


5350 South Roslyn, Suite 430, Greenwood Village, CO
80111
(Address of principal executive offices)
(Zip Code)
 
(303) 867-3415
(Registrant’s telephone number, including area code)
 
 
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

Item 7.01              Regulation FD Disclosure.

On January 31, 2013, Omni Bio Pharmaceutical, Inc. issued a press release announcing the issuance of a Company update letter to its shareholders dated January 31, 2013 (“Shareholder Letter”).  A copy of the press release and the Shareholder Letter are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively.


Item 9.01              Financial Statements and Exhibits.

(d)  Exhibits.

99.1
Press Release of Omni Bio Pharmaceutical, Inc. dated January 31, 2013
99.2
Shareholder Letter dated January 31, 2013

 
 

 
 
SIGNATURES
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Omni Bio Pharmaceutical, Inc.  
     
     
     
Date: January 31, 2013    
     
  By: /s/ Robert C. Ogden  
  Robert C. Ogden  
  Chief Financial Officer  

 
 

 
 
Exhibit Index

 
Exhibit No.   Description                                                 
     
99.1   Press Release of Omni Bio Pharmaceutical, Inc. dated January 31, 2013
99.2   Shareholder Letter dated January 31, 2013